High-dose liver treatment plus standard chemotherapy versus standard chemotherapy alone for breast cancer spread to liver

Plain-English translation of NCT06875128 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a new approach for people whose breast cancer has spread mainly to the liver. The treatment uses melphalan, a high-dose chemotherapy drug that is delivered directly into the liver through a catheter placed in an artery, followed by one of three standard cancer medications. Researchers want to see if this liver-directed approach works better than standard chemotherapy alone, and whether it is safe and tolerable.

When breast cancer spreads to the liver, it can be especially difficult to treat. This trial exists to see if delivering strong chemotherapy directly to the liver—where most of the cancer is located—might control the disease better than treating it with standard medications given throughout the body.

Do you qualify?

You likely qualify if…

you have been diagnosed with metastatic breast cancer (cancer that has spread beyond the breast) that does not have too much HER2 protein
your cancer has spread mainly to the liver, with the majority of your tumor burden located there
you have already tried other cancer treatments and your disease has gotten worse or you could not tolerate those treatments
your liver tumors take up 50% or less of your liver tissue
you are in good enough health to receive general anesthesia and to handle chemotherapy
any cancer outside the liver is limited and not life-threatening

You likely don't qualify if…

you have had previous chemotherapy delivered directly into the liver or liver artery
you have signs of severe liver disease, such as enlarged veins in your abdomen or esophagus that could bleed
you have serious heart problems or active heart disease that would make general anesthesia too risky
you have significant lung disease that would make general anesthesia unsafe
you have a history of bleeding problems or brain tumors

What participation looks like

Participants will be randomly assigned to one of two groups. One group will receive up to two cycles of the high-dose liver treatment (done under general anesthesia in a hospital setting) followed by standard chemotherapy, while the other group will receive standard chemotherapy alone. You will visit the clinic at least every two weeks for checkups, blood tests, and other monitoring, and you will have imaging scans (CT or MRI) approximately every 8 weeks to see how the treatment is working.

AI-generated summary from trial data · Jun 6, 2026 · Not medical advice

High-dose liver treatment plus standard chemotherapy versus standard chemotherapy alone for breast cancer spread to liver

What is this trial?

Do you qualify?

What participation looks like

Trial locations(5 sites)